Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SPIRONOLACTONE Cause Therapeutic product effect incomplete? 315 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 315 reports of Therapeutic product effect incomplete have been filed in association with SPIRONOLACTONE (spironolactone). This represents 1.5% of all adverse event reports for SPIRONOLACTONE.

315
Reports of Therapeutic product effect incomplete with SPIRONOLACTONE
1.5%
of all SPIRONOLACTONE reports
4
Deaths
215
Hospitalizations

How Dangerous Is Therapeutic product effect incomplete From SPIRONOLACTONE?

Of the 315 reports, 4 (1.3%) resulted in death, 215 (68.3%) required hospitalization.

Is Therapeutic product effect incomplete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SPIRONOLACTONE. However, 315 reports have been filed with the FAERS database.

What Other Side Effects Does SPIRONOLACTONE Cause?

Acute kidney injury (3,273) Hyperkalaemia (2,518) Hypotension (1,583) Dyspnoea (1,468) Drug ineffective (1,379) Hyponatraemia (1,166) Dizziness (991) Fatigue (990) Fall (947) Off label use (899)

What Other Drugs Cause Therapeutic product effect incomplete?

ALBUTEROL (8,496) ADALIMUMAB (6,986) PREDNISONE (6,709) METHOTREXATE (6,037) TOFACITINIB (4,914) SECUKINUMAB (4,661) BUDESONIDE\FORMOTEROL (4,392) TIOTROPIUM (4,327) MEPOLIZUMAB (4,106) ETANERCEPT (3,961)

Which SPIRONOLACTONE Alternatives Have Lower Therapeutic product effect incomplete Risk?

SPIRONOLACTONE vs SPRYCEL SPIRONOLACTONE vs STALEVO SPIRONOLACTONE vs STANNOUS FLUORIDE SPIRONOLACTONE vs STANOZOLOL SPIRONOLACTONE vs STAVUDINE

Related Pages

SPIRONOLACTONE Full Profile All Therapeutic product effect incomplete Reports All Drugs Causing Therapeutic product effect incomplete SPIRONOLACTONE Demographics